New Bayer site to make traditional Chinese and Western consumer health meds

Bayer snapped up China's Dihon in 2014 with the idea of combining Dihon's traditional Chinese medicines with Bayer's Western OTC products in a major consumer health play in the country. Now it has a large new plant there to produce both kinds of products. Last week, the drugmaker opened the first phase of a CNY 1.4 billion ($213 million), plant, which at 111,534 square meters (1,200,542 square feet) is Bayer's second largest OTC facility in the Asia Pacific. It will soon be producing Bayer's key TCM product, Dan E Fu Kang, which is marketed as a gynecological medicine for women's health indications including dysmenorrhea. More from FiercePharmaManufacturing | More

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.